UC Regents vs. Broad Institute: Federal Circuit Vacates CRISPR Patent Conception Ruling
What would you like to do next?
Explore the implications of this landmark CRISPR ruling:
📋 Case Summary
| Case Name | The Regents of the University of California v. The Broad Institute, Inc. |
| Case Number | 22-1594 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from PTAB |
| Duration | Apr 2022 – May 2025 3 years 1 month |
| Outcome | Split Decision – Remand for Conception |
| Patents at Issue | |
| Technology at Issue | CRISPR-Cas9 Gene-Editing Systems and Methods |
Case Overview
The Parties
⚖️ Plaintiff
Represents one of the nation’s premier public research systems, asserting rights stemming from the laboratory of Nobel Laureate Jennifer Doudna. UC’s CRISPR patent portfolio underpins a wide range of therapeutic and agricultural biotechnology applications globally.
🛡️ Defendant
A joint research initiative of MIT and Harvard, holding competing CRISPR patent rights derived from the work of Feng Zhang. The Broad’s patents have been central to commercial licensing arrangements with major pharmaceutical and biotech companies.
The Patent at Issue
This landmark case involved U.S. Patent No. 8,697,359, covering foundational CRISPR-Cas9 gene-editing technology—arguably the most commercially valuable patent in modern life sciences:
- • US 8,697,359 B1 — Covers core mechanisms enabling precise genomic editing — the foundational layer of a multi-billion-dollar therapeutic pipeline.
Innovating in the CRISPR space?
Check if your gene-editing technology might face priority challenges or infringe related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a multi-part disposition: **affirmed** the Patent Trial and Appeal Board’s (PTAB) written description ruling, **vacated** its conception determination, and **remanded** the case for further proceedings. No damages were awarded at this appellate stage, consistent with the proceeding’s nature as a patentability/validity dispute.
Key Legal Issues
The Federal Circuit upheld PTAB’s written description analysis under 35 U.S.C. § 112, affirming that the relevant patent disclosure adequately supported its claims. However, the court found that PTAB applied an **incorrect legal standard** when evaluating conception — the mental formulation of a complete and operative invention. This vacatur requires PTAB to re-examine the conception timeline using the proper framework, potentially reopening priority arguments.
Developing new gene-editing techniques?
Learn from this case. Use AI to draft stronger claims for your biotechnology inventions.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ CRISPR & Gene-Editing FTO Analysis
This landmark case highlights critical IP risks in foundational biotechnology. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related CRISPR patents
- See key inventors and assignees
- Understand claim construction patterns for gene-editing
🔍 Check My Technology’s Risk
Run a comprehensive FTO analysis for your own gene-editing technology or product.
- Input your technology description or features
- AI identifies potentially blocking patents in CRISPR
- Get actionable risk assessment report
High Risk Area
Foundational CRISPR-Cas9 methods
400+ Related Patents
In CRISPR-Cas9 space
Ongoing Uncertainty
Priority dispute unresolved
✅ Key Takeaways
For Patent Attorneys
Federal Circuit vacated PTAB’s conception analysis for applying an incorrect legal standard — a reminder that pure legal errors at the Board remain fully reviewable on appeal.
Search related case law →Written description affirmance confirms rigorous § 112 scrutiny applies to complex biotech disclosures.
Explore precedents →For IP Professionals
CRISPR patent ownership remains unresolved; licensing portfolios tied to either institution carry continued uncertainty.
Start FTO analysis for my product →Monitor PTAB remand proceedings for updated priority determinations affecting downstream licensing.
Try AI patent drafting →For R&D Leaders
Do not treat CRISPR licensing arrangements as fully settled pending PTAB remand.
Explore CRISPR landscape →Maintain contemporaneous invention records to support conception arguments in any future priority dispute.
Secure your IP →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.